The tumor microenvironment plays a pivotal role in tumor initiation and progression by
creating a dynamic interaction with cancer cells. The tumor microenvironment consists of …

The introduction of immunotherapies has been a major development in the treatment of
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …

In treatments of solid tumors, adoptive transfer of ex vivo expanded natural killer (NK) cells
has dawned as a new paradigm. Compared with cytotoxic T lymphocytes, NK cells take a …

Natural killer (NK) cells account for 25–50% of the total number of hepatic lymphocytes,
which implicates that NK cells play an important role in liver immunity. The frequencies of …

Sorafenib, FDA-approved therapy for patients with advanced hepatocellular carcinoma
(HCC), leads to limited improvement in overall survival. However, it may indirectly impact the …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

Rationale: Protein kinases are critical therapeutic targets for curing hepatocellular
carcinoma (HCC). As a serine/threonine kinase, the potential roles of serine/threonine …

Background Hepatocellular carcinoma (HCC) has a poor prognosis and has become the
sixth most common malignancy worldwide due to its high incidence. Advanced approaches …

According to data provided by WHO (World Health Organization), hepatocellular carcinoma
(HCC) is the fourth most common cause of cancer-related deaths worldwide. Since the …